Tesamorelin fat loss: Frequently asked questions

Skip that dose and wait until the next scheduled injection. Elevated insulin from recent food intake will block hormone-sensitive lipase activation through PDE3B upregulation. Injecting during this window wastes the peptide without producing lipolytic effect. Insulin levels return to baseline approximately 3 hours after a mixed meal; injecting before this window means you're fighting the mechanism you're trying to activate. Our experience shows researchers who maintain strict meal-to-injection spacing see 40–60% better VAT reduction than those who inject inconsistently relative to meals.

Discard it. Lyophilized peptides are stable at room temperature before reconstitution, but once mixed with bacteriostatic water, the protein structure begins degrading rapidly above 8°C. A single temperature excursion above 15°C for 6–8 hours denatures enough of the peptide to render it inactive. There is no visual indicator of this degradation. Refrigeration at 2–8°C is mandatory from the moment you add bacteriostatic water until the vial is empty. This is the single most common protocol failure we see across research settings.

Administer the missed dose as soon as you remember, provided it's still at least 3 hours post-meal and you can inject before eating breakfast the next morning. If you wake up and it's already morning, skip the missed dose entirely and resume your regular schedule that evening. Do not double-dose. Tesamorelin does not require daily dosing to maintain steady-state plasma levels the way longer-acting peptides do; missing one or two doses per month will not significantly impact cumulative VAT reduction over a 26-week protocol.

Plateau is expected. Clinical data show VAT loss slows significantly after week 20–26 regardless of continued dosing. If the goal is further reduction, the evidence suggests discontinuing tesamorelin for 8–12 weeks to allow receptor sensitivity to reset, then restarting at 2mg daily for another 26-week cycle. Alternatively, addressing dietary composition. Specifically reducing fructose intake, which preferentially refills hepatic and visceral fat stores. May allow continued VAT mobilisation even as GH-mediated lipolysis slows. The research is clear: tesamorelin is a catalyst for VAT reduction, not a substitute for metabolic interventions that prevent VAT reaccumulation.

Verify peptide purity first. If third-party HPLC analysis confirms >98% purity and proper storage was maintained, the issue is likely administration technique or timing. Tesamorelin must be injected subcutaneously. Intramuscular injection alters absorption kinetics and reduces peak GH response. Injection timing also matters: evening administration (8–10 PM) aligns with natural GH pulsatility, while morning injections may be blunted by cortisol's GH-suppressing effect. If technique and timing are correct but IGF-1 remains flat, consider GH resistance secondary to liver dysfunction or hypothyroidism, both of which impair hepatic IGF-1 synthesis downstream of GH receptor activation.

Discard it. Lyophilised tesamorelin must be stored at −20°C before reconstitution, and reconstituted solutions require refrigeration at 2–8°C. Any temperature excursion above 8°C for more than 2–4 hours causes irreversible denaturation of the peptide's tertiary structure, rendering it pharmacologically inactive. Visual inspection cannot detect this degradation. The solution may appear clear and sterile but produce zero IGF-1 elevation when administered. Researchers who ignore cold-chain requirements are the most common source of 'non-responder' reports in online forums.